Tonix Pharmaceuticals (TNXP) Gains Following Positive FDA Update on TNX-102 SL in PTSD

August 29, 2016 8:39 AM EDT
Get Alerts TNXP Hot Sheet
Trade TNXP Now!
Join SI Premium – FREE

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

Tonix Pharmaceuticals (NASDAQ: TNXP) is gaining 15.6% early after the company announced that it has received the final meeting minutes from the U.S. Food and Drug Administration (FDA) from an End-of-Phase 2/Pre-Phase 3 meeting. These minutes confirmed the FDA’s acceptance of Tonix’s proposed Phase 3 studies and the planned New Drug Application (NDA) data package to support the registration of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for the treatment of PTSD.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

FDA, Momentum Movers, Trader Talk

Add Your Comment